Sec. 3223. GAO study and report on hospice safe drug management
181 words·~1 min read·
/bill/115/hr/6/eah/section-3223A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Comptroller General of the United States (in this section referred to as the Comptroller General ) shall conduct a study on the requirements applicable to, and challenges of, hospice programs with regard to the management and disposal of controlled substances in the home of an individual. In conducting the study under paragraph (1), the Comptroller General shall include— an overview of any challenges encountered by selected hospice programs regarding the disposal of controlled substances, such as opioids, in a home setting, including any key changes in policies, procedures, or best practices for the disposal of controlled substances over time; and a description of Federal requirements, including requirements under the Medicare program, for hospice programs regarding the disposal of controlled substances in a home setting, and oversight of compliance with those requirements.
Not later than 18 months after the date of enactment of this Act, the Comptroller General shall submit to Congress a report containing the results of the study conducted under subsection (a), together with recommendations, if any, for such legislation and administrative action as the Comptroller General determines appropriate.